Top Page
CVS Group plc
(LSE:CVSG)
CVS Group plc (CVSG) vs. iShares MSCI United Kingdom ETF (EWC)
CVS Group plc Business Overview & Revenue Model
CVS Group plc Earnings Call Summary
CVS Group plc Financial Statement Overview
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 688.30M | 673.20M | 647.30M | 588.90M | 554.20M | 510.10M |
| Gross Profit | 268.60M | 259.70M | 277.90M | 262.30M | 239.10M | 221.90M |
| EBITDA | 123.30M | 114.30M | 108.40M | 118.80M | 90.40M | 88.20M |
| Net Income | 15.90M | 19.30M | 6.20M | 41.90M | 25.70M | 19.30M |
Balance Sheet | ||||||
| Total Assets | 716.90M | 696.20M | 690.00M | 572.30M | 518.20M | 484.50M |
| Cash, Cash Equivalents and Short-Term Investments | 12.30M | 16.10M | 16.50M | 21.50M | 49.00M | 33.70M |
| Total Debt | 358.60M | 248.80M | 287.80M | 199.10M | 188.80M | 182.70M |
| Total Liabilities | 417.00M | 394.50M | 429.50M | 315.30M | 300.80M | 293.40M |
| Stockholders Equity | 295.10M | 299.80M | 260.40M | 257.00M | 217.40M | 191.10M |
Cash Flow | ||||||
| Free Cash Flow | 57.20M | 55.70M | 24.70M | 38.80M | 51.00M | 43.60M |
| Operating Cash Flow | 82.30M | 82.10M | 67.80M | 84.50M | 75.50M | 60.20M |
| Investing Cash Flow | -22.90M | -22.70M | -140.50M | -99.90M | -45.10M | -35.40M |
| Financing Cash Flow | -57.80M | -59.20M | 68.30M | -12.10M | -15.10M | -12.60M |
CVS Group plc Technical Analysis
CVS Group plc Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | £68.44M | -44.80 | 3.62% | ― | 1.44% | 359.79% | |
74 Outperform | £182.14M | 12.60 | 20.31% | 3.48% | 10.80% | 1.75% | |
69 Neutral | £1.86B | 14.39 | 3.77% | 1.25% | 0.60% | 143.39% | |
67 Neutral | £186.42M | 15.48 | 2.83% | 2.18% | 8.74% | -166.50% | |
67 Neutral | £109.25M | 15.58 | 8.71% | ― | -1.43% | 28.57% | |
66 Neutral | £907.82M | 29.48 | 6.75% | 0.67% | 4.00% | -6.98% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
CVS Group plc Corporate Events
CVS Group reported a 5.8% rise in revenue from continuing operations to £356.9m and a 3.9% increase in adjusted EBITDA to £67.7m for the six months to 31 December 2025, despite softer UK market conditions. Profit before tax fell 4.4% to £15.2m due to higher non-cash depreciation, acquisition-related costs, and exceptional items linked to the CMA inquiry and its move to the London Stock Exchange Main Market.
The group continued to expand in Australia, completing two practice acquisitions during the period and further deals post period-end, while investing £17.5m in relocations, refurbishments, and clinical equipment to boost capacity and standards of care. Its Main Market listing and expected FTSE 250 inclusion are set to improve access to capital and liquidity, supporting a strong acquisition pipeline and positioning CVS for medium- to long-term growth, even as UK consumer confidence remains weak and regulatory scrutiny continues.
The most recent analyst rating on (GB:CVSG) stock is a Hold with a £1480.00 price target. To see the full list of analyst forecasts on CVS Group plc stock, see the GB:CVSG Stock Forecast page.
CVS Group plc has confirmed that its total issued share capital stands at 70,156,093 ordinary shares, each carrying one voting right, with no shares held in treasury. This establishes the company’s total voting rights at 70,156,093, a figure shareholders must use as the denominator when assessing whether they are required to notify the regulator of any holdings or changes in holdings under UK disclosure and transparency rules.
The most recent analyst rating on (GB:CVSG) stock is a Hold with a £1442.00 price target. To see the full list of analyst forecasts on CVS Group plc stock, see the GB:CVSG Stock Forecast page.
CVS Group plc has completed its move from AIM to the Main Market of the London Stock Exchange, with its ordinary shares admitted today to the FCA’s Official List and trading on the Main Market under the existing ticker CVSG. No new shares or capital are being raised as part of the transition, leaving the total number of ordinary shares in issue at 70,156,093, a structure that may support potential index inclusion, broaden the investor base and enhance trading liquidity. Chair David Wilton framed the move as a key milestone that reflects management’s confidence in the group’s future growth prospects and is intended to strengthen CVS’s corporate profile and access to deeper capital pools, with implications for improved market visibility and long‑term value creation for shareholders and other stakeholders.
The most recent analyst rating on (GB:CVSG) stock is a Hold with a £1436.00 price target. To see the full list of analyst forecasts on CVS Group plc stock, see the GB:CVSG Stock Forecast page.
CVS Group has welcomed the UK Government’s decision to launch an eight-week consultation on reforms to the Veterinary Surgeons Act 1966, a move that stems from recommendations made by the Competition and Markets Authority following its market investigation into household pet veterinary services. The company, which has long advocated modernisation of the Act, argues that reform will bolster consumer confidence, introduce stronger practice-level regulation such as mandatory adherence to the Practice Standards Scheme, and expand the role of Registered Veterinary Nurses to perform a broader range of procedures; CVS also reaffirmed that it expects to deliver its FY2026 results in line with the board’s expectations, signalling operational stability as regulatory changes are explored.
The most recent analyst rating on (GB:CVSG) stock is a Hold with a £1431.00 price target. To see the full list of analyst forecasts on CVS Group plc stock, see the GB:CVSG Stock Forecast page.
CVS Group plc has published a prospectus ahead of moving its existing ordinary shares from AIM to the Main Market of the London Stock Exchange on 29 January 2026, without raising new capital, a step that is expected to enhance its market profile while maintaining its current ticker and ISIN. In an accompanying trading update for the six months to 31 December 2025, the company reported 5.8% revenue growth to £356.9m and a 3.9% rise in adjusted EBITDA to £67.7m, alongside ongoing investment in technology and practice infrastructure, the rollout of its new ‘CVS Vets’ dual branding in UK companion animal sites, and continued expansion in Australia, where it now operates 32 practices across 54 sites. Employee engagement showed improvement, leverage rose in line with expectations to 1.41x following capital expenditure, acquisitions and a share buyback, and the group said performance remains on track with full-year expectations despite UK consumer headwinds, while it continues to engage with the Competition and Markets Authority on proposed remedies arising from the sector-wide market investigation.
The most recent analyst rating on (GB:CVSG) stock is a Hold with a £1465.00 price target. To see the full list of analyst forecasts on CVS Group plc stock, see the GB:CVSG Stock Forecast page.
CVS Group plc has completed its previously announced share buyback programme of up to £20 million, purchasing a final tranche of 51,698 ordinary shares on 22 January 2026 at prices between 1,330p and 1,348p per share. All shares repurchased under the programme, totalling 1,584,690 ordinary shares at an average price of 1,262.08p and an aggregate cost of £19,999,995.20, will be cancelled, reducing the company’s share count to 70,156,093 in issue and leaving no shares held in treasury. The completion of the buyback tightens CVS’s share capital base and recalibrates total voting rights, a move likely to enhance earnings per share and marginally increase existing shareholders’ relative ownership stakes.
The most recent analyst rating on (GB:CVSG) stock is a Hold with a £1465.00 price target. To see the full list of analyst forecasts on CVS Group plc stock, see the GB:CVSG Stock Forecast page.
CVS Group plc has continued to execute its previously announced share buyback programme, repurchasing 52,278 ordinary shares on 21 January 2026 at prices between 1,304p and 1,340p, with a volume-weighted average price of 1,319.53p per share. The company intends to cancel all of these shares, reducing the total number of shares in issue to 70,207,791 and leaving no shares held in treasury, which in turn sets the new baseline for shareholders’ voting-rights calculations. Since the start of the buyback initiative in October 2025, CVS has now repurchased a total of 1,532,992 shares at a weighted average price of 1,259.43p, underlining an ongoing capital management strategy that tightens the share count and may enhance earnings per share and support the stock’s valuation.
The most recent analyst rating on (GB:CVSG) stock is a Hold with a £1465.00 price target. To see the full list of analyst forecasts on CVS Group plc stock, see the GB:CVSG Stock Forecast page.
CVS Group plc has repurchased 50,918 of its ordinary shares on 20 January 2026 under its ongoing share buyback programme, paying between 1,340p and 1,364p per share at a volume-weighted average price of 1,354.88p. The company intends to cancel all of these shares, reducing its total shares in issue to 70,260,069 with no treasury shares, and bringing total buybacks under the programme to 1,480,714 shares at an average price of 1,257.31p, a move that tightens the share capital base and affects voting-right calculations for shareholders under UK disclosure rules.
The most recent analyst rating on (GB:CVSG) stock is a Hold with a £1465.00 price target. To see the full list of analyst forecasts on CVS Group plc stock, see the GB:CVSG Stock Forecast page.
CVS Group plc has continued its previously announced share buyback programme with the purchase of 50,329 ordinary shares on 19 January 2026 from Berenberg at prices between 1,366p and 1,376p, at a volume-weighted average price of 1,370.91p per share. The company intends to cancel these shares, reducing the total number of shares in issue to 70,310,987 and leaving no shares held in treasury, which in turn sets the new denominator for shareholder voting-rights calculations under UK disclosure rules; cumulatively, CVS has now repurchased 1,429,796 shares since the programme began, signalling an ongoing capital return strategy that modestly enhances earnings per share and may be interpreted as management confidence in the company’s valuation.
The most recent analyst rating on (GB:CVSG) stock is a Hold with a £1465.00 price target. To see the full list of analyst forecasts on CVS Group plc stock, see the GB:CVSG Stock Forecast page.
CVS Group plc has continued to execute its previously announced share buyback programme, repurchasing 50,275 ordinary shares on 16 January 2026 at prices between 1,360p and 1,376p per share, with a volume-weighted average price of 1,372.35p. The company intends to cancel these shares, reducing its total shares in issue to 70,361,316 and leaving no shares held in treasury, which in turn sets the new total voting rights figure used for regulatory disclosure thresholds. Since the start of the buyback in October 2025, CVS has bought back 1,379,467 shares at an average price of 1,249.57p, underlining an ongoing capital management strategy that modestly enhances earnings per share and may signal management’s confidence in the company’s valuation to investors.
The most recent analyst rating on (GB:CVSG) stock is a Hold with a £1472.00 price target. To see the full list of analyst forecasts on CVS Group plc stock, see the GB:CVSG Stock Forecast page.
CVS Group plc has continued its previously announced share buyback programme with the repurchase of 50,656 ordinary shares on 15 January 2026 at prices between 1,350p and 1,374p, for a volume-weighted average price of 1,362.05p per share. All of the shares bought back will be cancelled, reducing the company’s issued share capital to 70,411,591 ordinary shares and leaving no shares held in treasury, a move that marginally increases existing shareholders’ relative stakes and may signal management’s confidence in the company’s valuation; since the programme began, CVS has bought back 1,329,192 shares at an average price of 1,244.92p, underlining an ongoing capital management strategy that could support earnings per share and shareholder returns.
The most recent analyst rating on (GB:CVSG) stock is a Hold with a £1438.00 price target. To see the full list of analyst forecasts on CVS Group plc stock, see the GB:CVSG Stock Forecast page.
CVS Group plc has continued its previously announced share buyback programme with the repurchase of 50,656 ordinary shares on 15 January 2026 at prices between 1,350p and 1,374p, for a volume-weighted average price of 1,362.05p per share. All of the shares bought back will be cancelled, reducing the company’s issued share capital to 70,411,591 ordinary shares and leaving no shares held in treasury, a move that marginally increases existing shareholders’ relative stakes and may signal management’s confidence in the company’s valuation; since the programme began, CVS has bought back 1,329,192 shares at an average price of 1,244.92p, underlining an ongoing capital management strategy that could support earnings per share and shareholder returns.
The most recent analyst rating on (GB:CVSG) stock is a Hold with a £1438.00 price target. To see the full list of analyst forecasts on CVS Group plc stock, see the GB:CVSG Stock Forecast page.
CVS Group plc has continued to execute its previously announced share buyback programme, repurchasing 29,492 ordinary shares on 14 January 2026 at prices between 1,336p and 1,352p per share, with a volume-weighted average price of 1,348.42p. All of these shares will be cancelled, reducing the company’s share count to 70,462,247 and leaving no shares held in treasury, which marginally increases existing shareholders’ proportional ownership and voting power; since the start of the programme, CVS has bought back a total of 1,278,536 shares at a weighted average price of 1,240.28p, underlining an ongoing capital management strategy that may signal confidence in the company’s valuation and earnings outlook.
The most recent analyst rating on (GB:CVSG) stock is a Hold with a £1431.00 price target. To see the full list of analyst forecasts on CVS Group plc stock, see the GB:CVSG Stock Forecast page.
CVS Group plc has continued execution of its previously announced share buyback programme, repurchasing 29,885 ordinary shares on 13 January 2026 at prices between 1,334p and 1,362p per share, with a volume-weighted average price of 1,354.33p. All of these shares will be cancelled, reducing the number of ordinary shares in issue to 70,491,739 and leaving no shares held in treasury, while total repurchases under the programme now stand at 1,249,044 shares at a weighted average price of 1,237.73p, a move that marginally enhances earnings per share and may signal management’s confidence in the company’s valuation to investors.
The most recent analyst rating on (GB:CVSG) stock is a Hold with a £1308.00 price target. To see the full list of analyst forecasts on CVS Group plc stock, see the GB:CVSG Stock Forecast page.
CVS Group plc has continued its previously announced share buyback programme with the repurchase on 12 January 2026 of 29,888 ordinary shares at prices between 1,342p and 1,360p, at a volume-weighted average price of 1,352.20p per share, from Joh. Berenberg, Gossler & Co. KG. The company intends to cancel all of these shares, leaving 70,521,624 ordinary shares in issue and no treasury shares, and has now bought back a total of 1,219,159 shares since the start of the programme at an average price of 1,234.87p, reducing share capital and slightly increasing remaining shareholders’ proportional ownership and voting rights.
The most recent analyst rating on (GB:CVSG) stock is a Hold with a £1308.00 price target. To see the full list of analyst forecasts on CVS Group plc stock, see the GB:CVSG Stock Forecast page.
CVS Group plc, a leading veterinary services provider listed on AIM with extensive UK and Australian operations, has continued to expand its footprint across clinical practices, laboratories and online retail while focusing on high-quality animal care delivered by large teams of vets and nurses. The company has repurchased 30,119 of its own ordinary shares on 9 January 2026 under its ongoing share buyback programme, at a volume-weighted average price of 1,344.63 pence, and intends to cancel these shares, reducing the number of shares in issue to 70,551,512 and leaving no treasury shares. Since the buyback’s launch in October 2025, CVS has bought back 1,189,271 shares at an average price of 1,231.92 pence, a move that tightens its share capital and may enhance earnings per share and shareholder value by concentrating voting rights among remaining investors.
The most recent analyst rating on (GB:CVSG) stock is a Hold with a £1320.00 price target. To see the full list of analyst forecasts on CVS Group plc stock, see the GB:CVSG Stock Forecast page.
CVS Group plc has continued to execute its previously announced share buyback programme, repurchasing 30,898 ordinary shares on 8 January 2026 at prices between 1,298p and 1,326p per share, with a volume-weighted average price of 1,310.61p. The company plans to cancel all of these shares, leaving 70,581,631 ordinary shares in issue and no shares held in treasury, and it has now bought back a total of 1,159,152 shares since the programme began, a move that reduces the share count and may enhance earnings per share while clarifying the current total of voting rights for investors under regulatory disclosure rules.
The most recent analyst rating on (GB:CVSG) stock is a Hold with a £1320.00 price target. To see the full list of analyst forecasts on CVS Group plc stock, see the GB:CVSG Stock Forecast page.
CVS Group plc has continued its share buyback programme with the repurchase of 31,334 ordinary shares on 7 January 2026 from Berenberg at prices ranging between 1,282p and 1,334p per share, at a volume-weighted average price of 1,292.16p. The company intends to cancel all of these shares, reducing its issued share capital to 70,612,529 ordinary shares and leaving no shares held in treasury; since the start of the buyback in October 2025, CVS has bought back a total of 1,128,254 shares, a move that tightens the share base and may enhance earnings per share and voting power for remaining investors.
The most recent analyst rating on (GB:CVSG) stock is a Hold with a £1320.00 price target. To see the full list of analyst forecasts on CVS Group plc stock, see the GB:CVSG Stock Forecast page.
CVS Group plc has repurchased 31,375 of its ordinary shares on 6 January 2026 under its ongoing share buyback programme, paying between 1,272p and 1,302p per share at a volume-weighted average price of 1,290.66p. The company intends to cancel these shares, reducing its total shares in issue to 70,643,863 and leaving no shares held in treasury, with the total voting rights now standing at the same figure. Since the buyback programme began in October 2025, CVS has bought back 1,096,920 shares at a weighted average price of 1,224.89p, signalling continued capital management aimed at enhancing shareholder value and slightly increasing existing investors’ proportional ownership and voting power.
The most recent analyst rating on (GB:CVSG) stock is a Hold with a £1320.00 price target. To see the full list of analyst forecasts on CVS Group plc stock, see the GB:CVSG Stock Forecast page.
CVS Group plc reported that non-executive director Richard Gray has increased his personal stake in the company by purchasing 2,000 ordinary shares on 5 January 2026 via an on-market transaction on AIM. Following this purchase, Gray’s total holding, including those of persons closely associated with him, stands at 9,600 shares, representing approximately 0.014% of CVS’s voting rights, a modest but positive signal of board-level confidence in the veterinary group.
The most recent analyst rating on (GB:CVSG) stock is a Hold with a £1320.00 price target. To see the full list of analyst forecasts on CVS Group plc stock, see the GB:CVSG Stock Forecast page.
CVS Group plc has repurchased 16,337 of its own ordinary shares on 5 January 2026 as part of the share buyback programme launched in October 2025, at prices between 1,262p and 1,282p per share and a volume-weighted average of 1,273.40p. The company intends to cancel all of these shares, reducing the total number of shares in issue to 70,675,238 and leaving no treasury shares, bringing total repurchases under the programme to 1,065,545 shares; this buyback and cancellation marginally increases remaining shareholders’ proportional ownership and clarifies the voting rights base for regulatory disclosure purposes.
The most recent analyst rating on (GB:CVSG) stock is a Hold with a £1320.00 price target. To see the full list of analyst forecasts on CVS Group plc stock, see the GB:CVSG Stock Forecast page.
CVS Group plc has continued its existing share buyback programme by purchasing 15,144 ordinary shares on 2 January 2026 at a volume-weighted average price of 1,283.48 pence per share from Berenberg. The company intends to cancel all the shares bought back, reducing the number of shares in issue to 70,691,575 and leaving no shares held in treasury; in total, since launching the programme in October 2025, CVS has repurchased 1,049,208 shares, a move that consolidates voting rights and is likely to enhance earnings per share for remaining investors.
The most recent analyst rating on (GB:CVSG) stock is a Hold with a £1320.00 price target. To see the full list of analyst forecasts on CVS Group plc stock, see the GB:CVSG Stock Forecast page.
CVS Group plc has continued its previously announced share buyback programme, repurchasing 4,554 ordinary shares on 31 December 2025 at a volume-weighted average price of 1,273.59 pence per share from Berenberg. The company intends to cancel these shares, reducing the total number of ordinary shares in issue to 70,706,719 and leaving no shares held in treasury, which in turn sets the new baseline for shareholder voting rights disclosures under UK regulatory rules. Since launching the programme in October 2025, CVS has bought back a total of 1,034,064 shares at a weighted average price of 1,221.27 pence, signalling ongoing capital management and a potential enhancement of earnings per share for existing investors through a reduced share count.
The most recent analyst rating on (GB:CVSG) stock is a Hold with a £1320.00 price target. To see the full list of analyst forecasts on CVS Group plc stock, see the GB:CVSG Stock Forecast page.
CVS Group plc has continued to execute its share buyback programme, repurchasing 7,816 ordinary shares on 30 December 2025 at prices between 1,266p and 1,284p per share, with a volume-weighted average price of 1,278.10p. The company intends to cancel these shares, leaving 70,711,273 ordinary shares in issue and no shares held in treasury, bringing total repurchases under the programme to 1,029,510 shares at an average price of 1,221.04p, and slightly enhancing earnings per share and voting interests for remaining shareholders.
The most recent analyst rating on (GB:CVSG) stock is a Hold with a £1320.00 price target. To see the full list of analyst forecasts on CVS Group plc stock, see the GB:CVSG Stock Forecast page.
CVS Group plc has updated the market on its total voting rights following the cancellation of ordinary shares repurchased under its share buyback programme announced in October 2025. As of 31 December 2025, the company’s issued share capital comprises 70,711,273 ordinary shares of 0.2p each, a figure that now serves as the reference point for shareholders assessing disclosure obligations under the FCA’s transparency rules and reflects the impact of the capital management initiative on the group’s equity structure.
The most recent analyst rating on (GB:CVSG) stock is a Hold with a £1320.00 price target. To see the full list of analyst forecasts on CVS Group plc stock, see the GB:CVSG Stock Forecast page.
CVS Group plc has continued its share buyback programme with the purchase of 7,816 ordinary shares on 30 December 2025 at prices between 1,266p and 1,284p, for a volume-weighted average price of 1,278.10p per share. All of these shares will be cancelled, leaving 70,711,273 ordinary shares in issue and no treasury shares, setting the new total voting rights figure for investors’ disclosure calculations. Since the programme began in October, CVS has repurchased a total of 1,029,510 shares at a weighted average price of 1,221.04p, underscoring ongoing capital management efforts that modestly reduce the company’s share count and may enhance earnings per share and shareholder value over time.
The most recent analyst rating on (GB:CVSG) stock is a Hold with a £1320.00 price target. To see the full list of analyst forecasts on CVS Group plc stock, see the GB:CVSG Stock Forecast page.
CVS Group plc has continued its previously announced share buyback programme with the repurchase on 29 December 2025 of 15,260 ordinary shares at prices between 1,268.00p and 1,282.00p, at a volume-weighted average price of 1,276.03p per share. The company intends to cancel these shares, which will leave 70,719,089 ordinary shares in issue and no shares held in treasury, setting the new total voting rights for regulatory disclosure purposes; since the launch of the programme, CVS has bought back 1,021,694 shares at an average price of 1,220.60p, signalling an ongoing effort to return capital to shareholders and optimise its capital structure.
The most recent analyst rating on (GB:CVSG) stock is a Hold with a £1320.00 price target. To see the full list of analyst forecasts on CVS Group plc stock, see the GB:CVSG Stock Forecast page.
CVS Group plc, the AIM-listed veterinary services provider operating roughly 470 practices across the UK and Australia, continues to focus on high-quality clinical care for companion animals through its extensive network of clinics and support teams. The company has repurchased 7,655 ordinary shares on 24 December 2025 under its ongoing share buyback programme, at a volume-weighted average price of 1,268.35 pence per share, and intends to cancel these shares, reducing its total shares in issue to 70,734,349 and leaving no treasury shares, which in turn sets the new baseline for voting rights calculations; since the buyback’s launch in October, CVS has bought back a total of 1,006,434 shares, signalling continued active capital management and potentially enhancing earnings per share and shareholder value.
The most recent analyst rating on (GB:CVSG) stock is a Hold with a £1320.00 price target. To see the full list of analyst forecasts on CVS Group plc stock, see the GB:CVSG Stock Forecast page.
CVS Group plc, the AIM-listed veterinary services provider with extensive operations across the UK and Australia, has continued to expand its integrated model of veterinary practices, laboratories and online retail, positioning itself as a major player in companion animal healthcare. The company disclosed that it repurchased 11,110 ordinary shares on 23 December 2025 under its ongoing share buyback programme, at prices between 1,264p and 1,274p per share and a volume-weighted average of 1,271.04p, and intends to cancel all of these shares, reducing the number of shares in issue to 70,742,004 with no treasury shares held. Since launching the buyback on 24 October 2025, CVS has bought back a total of 998,779 shares at an average price of 1,219.39p, a move that tightens its share capital and may enhance earnings per share, while updating investors on the new total voting rights figure used for regulatory disclosure thresholds.
The most recent analyst rating on (GB:CVSG) stock is a Hold with a £1320.00 price target. To see the full list of analyst forecasts on CVS Group plc stock, see the GB:CVSG Stock Forecast page.
CVS Group plc has continued its share buyback programme with the repurchase of 16,102 ordinary shares on 22 December 2025 at prices between 1,252p and 1,270p per share, for a volume-weighted average of 1,263.81p. The company will cancel these shares, reducing the number of shares in issue to 70,753,114 and leaving no shares held in treasury, a move that marginally enhances earnings per share and signals ongoing capital management discipline; since the programme began, CVS has bought back a total of 987,669 shares at an average price of 1,218.81p, refining its capital structure and potentially supporting shareholder value.
The most recent analyst rating on (GB:CVSG) stock is a Hold with a £1320.00 price target. To see the full list of analyst forecasts on CVS Group plc stock, see the GB:CVSG Stock Forecast page.
CVS Group plc has continued to execute its ongoing share buyback programme, repurchasing 14,156 ordinary shares on 19 December 2025 at prices between 1,254p and 1,270p per share, with a volume-weighted average price of 1,263.46p. The company intends to cancel these shares, leaving 70,769,216 ordinary shares in issue and no shares held in treasury, setting the new total voting rights for regulatory disclosure purposes; in aggregate since the start of the programme, CVS has bought back 971,567 shares at an average price of 1,218.06p, underscoring its active capital management and potential support for earnings per share.
The most recent analyst rating on (GB:CVSG) stock is a Hold with a £1320.00 price target. To see the full list of analyst forecasts on CVS Group plc stock, see the GB:CVSG Stock Forecast page.
CVS Group plc has continued to execute its previously announced share buyback programme, purchasing 18,123 ordinary shares on 18 December 2025 at prices between 1,248p and 1,268p per share, with a volume-weighted average price of 1,257.38p. The company intends to cancel all of these shares, leaving 70,783,372 ordinary shares in issue and no shares held in treasury, and has now repurchased a total of 957,411 shares at an average price of 1,217.39p since the programme began, effectively reducing its share capital and adjusting the total voting rights used by shareholders for regulatory disclosure thresholds.
The most recent analyst rating on (GB:CVSG) stock is a Hold with a £1320.00 price target. To see the full list of analyst forecasts on CVS Group plc stock, see the GB:CVSG Stock Forecast page.
CVS Group plc announced the purchase of 19,627 ordinary shares as part of its ongoing share buyback program. This strategic move, involving the cancellation of purchased shares, aims to enhance shareholder value and optimize the company’s capital structure, reducing the total number of shares in circulation to 70,801,495.
The most recent analyst rating on (GB:CVSG) stock is a Hold with a £1320.00 price target. To see the full list of analyst forecasts on CVS Group plc stock, see the GB:CVSG Stock Forecast page.
CVS Group plc has announced the purchase of 4,432 of its ordinary shares as part of a share buyback program initiated in October 2025. The shares were acquired at prices ranging from 1,228 to 1,248 pence per share, with an average price of 1,240.57 pence. Following this transaction, CVS intends to cancel the purchased shares, resulting in a total of 70,821,122 shares in issue. This move is part of CVS’s ongoing strategy to manage its share capital and potentially enhance shareholder value.
The most recent analyst rating on (GB:CVSG) stock is a Hold with a £1320.00 price target. To see the full list of analyst forecasts on CVS Group plc stock, see the GB:CVSG Stock Forecast page.
CVS Group plc announced the purchase of 4,432 of its own ordinary shares as part of a share buyback program initiated in October 2025. The shares were bought at prices ranging from 1,228.00 GBp to 1,248.00 GBp and will be canceled, reducing the total number of shares in issue to 70,821,122. This move is part of CVS’s ongoing strategy to manage its capital structure effectively, potentially improving shareholder value by reducing the number of shares outstanding.
The most recent analyst rating on (GB:CVSG) stock is a Hold with a £1320.00 price target. To see the full list of analyst forecasts on CVS Group plc stock, see the GB:CVSG Stock Forecast page.
CVS Group plc announced the purchase of 16,820 of its ordinary shares as part of its ongoing share buyback program, which was initially announced in October 2025. The company intends to cancel these shares, reducing the total number of shares in issue to 70,825,554. This move is part of CVS’s strategy to manage its capital structure and potentially enhance shareholder value.
The most recent analyst rating on (GB:CVSG) stock is a Hold with a £1320.00 price target. To see the full list of analyst forecasts on CVS Group plc stock, see the GB:CVSG Stock Forecast page.
CVS Group plc, a company involved in the veterinary services industry, has announced the purchase of 24,677 of its ordinary shares as part of its ongoing share buyback program. The shares were acquired from Joh. Berenberg, Gossler & Co. KG, London Branch, at prices ranging from 1,198.00 GBp to 1,224.00 GBp, with a volume-weighted average price of 1,215.60 GBp. The company plans to cancel these shares, reducing the total number of shares in issue to 70,842,374. This move is part of a broader strategy to manage the company’s capital structure and potentially enhance shareholder value.
The most recent analyst rating on (GB:CVSG) stock is a Hold with a £1320.00 price target. To see the full list of analyst forecasts on CVS Group plc stock, see the GB:CVSG Stock Forecast page.
CVS Group plc has announced the repurchase of 24,241 of its ordinary shares as part of its ongoing share buyback programme, initially announced in October 2025. The shares were purchased from Joh. Berenberg, Gossler & Co. KG, London Branch, at prices ranging from 1,206.00 GBp to 1,236.00 GBp, with a volume-weighted average price of 1,216.45 GBp. Following this transaction, CVS Group will cancel the purchased shares, resulting in a total of 70,867,051 ordinary shares in issue. This move is part of a broader strategy to manage the company’s capital structure and potentially enhance shareholder value.
The most recent analyst rating on (GB:CVSG) stock is a Hold with a £1320.00 price target. To see the full list of analyst forecasts on CVS Group plc stock, see the GB:CVSG Stock Forecast page.
CVS Group plc has announced its intention to move from AIM to the Main Market of the London Stock Exchange, with the transition expected to occur on January 29, 2026. This strategic move is aimed at enhancing the company’s market presence and visibility, although it requires several regulatory approvals. The transition will result in the cancellation of CVS’s shares from AIM, and shareholders are advised to seek financial guidance regarding this change.
The most recent analyst rating on (GB:CVSG) stock is a Hold with a £1420.00 price target. To see the full list of analyst forecasts on CVS Group plc stock, see the GB:CVSG Stock Forecast page.
CVS Group plc has announced the purchase of 24,425 of its ordinary shares as part of its ongoing share buyback program, with plans to cancel these shares. This transaction is part of a broader strategy to manage the company’s capital structure and enhance shareholder value, reducing the total number of shares in issue to 70,891,292. The buyback reflects CVS’s confidence in its financial position and commitment to returning value to shareholders, potentially impacting its market positioning by signaling financial stability and strategic focus.
The most recent analyst rating on (GB:CVSG) stock is a Hold with a £1420.00 price target. To see the full list of analyst forecasts on CVS Group plc stock, see the GB:CVSG Stock Forecast page.
CVS Group plc, a company involved in a share buyback program, announced the purchase of 20,428 ordinary shares from Joh. Berenberg, Gossler & Co. KG as part of its ongoing initiative. The shares were bought at prices ranging from 1,202.00 GBp to 1,230.00 GBp, with a volume-weighted average price of 1,222.04 GBp. Following this transaction, CVS will cancel the purchased shares, resulting in a total of 70,915,717 shares in issue, which impacts the voting rights and shareholding calculations under the Financial Conduct Authority’s rules. Since the start of the buyback program, CVS has repurchased a total of 825,066 shares.
The most recent analyst rating on (GB:CVSG) stock is a Hold with a £1420.00 price target. To see the full list of analyst forecasts on CVS Group plc stock, see the GB:CVSG Stock Forecast page.
CVS Group plc, a company involved in the veterinary services industry, has announced the repurchase of 24,910 of its ordinary shares as part of its ongoing share buyback program. This move is part of a broader strategy to manage its share capital and potentially enhance shareholder value. The purchased shares will be canceled, reducing the total number of shares in circulation to 70,936,145. This action reflects CVS’s commitment to optimizing its capital structure and could have implications for shareholder voting rights and market perception.
The most recent analyst rating on (GB:CVSG) stock is a Hold with a £1420.00 price target. To see the full list of analyst forecasts on CVS Group plc stock, see the GB:CVSG Stock Forecast page.
CVS Group plc announced that Paul Higgs, Director and Chief Veterinary Officer, and Joanne Shaw, Non-Executive Director, have purchased additional shares in the company. These transactions slightly increase their respective stakes in CVS, reflecting continued confidence in the company’s prospects and potentially impacting stakeholder perceptions positively.
The most recent analyst rating on (GB:CVSG) stock is a Hold with a £1420.00 price target. To see the full list of analyst forecasts on CVS Group plc stock, see the GB:CVSG Stock Forecast page.
CVS Group plc announced the purchase of 12,974 of its ordinary shares as part of its ongoing share buyback programme. The shares were acquired at a volume-weighted average price of 1,211.79 pence per share and will be cancelled, reducing the total number of shares in issue to 70,961,055. This move is part of CVS’s strategy to manage its capital structure and enhance shareholder value, reflecting confidence in the company’s financial health and future prospects.
The most recent analyst rating on (GB:CVSG) stock is a Hold with a £1420.00 price target. To see the full list of analyst forecasts on CVS Group plc stock, see the GB:CVSG Stock Forecast page.
CVS Group plc has announced the repurchase of 21,792 of its ordinary shares as part of its ongoing share buyback program. This transaction, executed on December 4, 2025, is part of a broader strategy to reduce the number of shares in circulation, potentially enhancing shareholder value. The company has repurchased a total of 766,754 shares since the program’s inception, with the latest shares being bought at prices ranging from 1,200.00 to 1,214.00 pence. Following this transaction, CVS Group plc will have 70,974,029 shares in issue, with no shares held in treasury, impacting the total voting rights available to shareholders.
The most recent analyst rating on (GB:CVSG) stock is a Hold with a £1420.00 price target. To see the full list of analyst forecasts on CVS Group plc stock, see the GB:CVSG Stock Forecast page.
CVS Group plc announced the purchase and subsequent cancellation of 24,653 of its ordinary shares as part of a share buyback program. This transaction is part of a broader initiative that has seen the company repurchase a total of 744,962 shares at an average price of 1,215.97 pence per share. The cancellation of these shares will reduce the total number of shares in issue to 70,995,821, impacting the voting rights and shareholding calculations under the Financial Conduct Authority’s rules. This move is likely aimed at enhancing shareholder value and optimizing the company’s capital structure.
The most recent analyst rating on (GB:CVSG) stock is a Hold with a £1420.00 price target. To see the full list of analyst forecasts on CVS Group plc stock, see the GB:CVSG Stock Forecast page.
CVS Group plc, a leading provider in the veterinary services industry, announced the purchase of 17,657 of its own ordinary shares as part of its ongoing share buyback program. This transaction, executed with Joh. Berenberg, Gossler & Co. KG, is part of a strategic initiative to enhance shareholder value. Following the cancellation of these shares, the total number of voting rights in the company will be adjusted to 71,020,474. This move is expected to impact the company’s market positioning by potentially increasing earnings per share and reflecting confidence in the company’s financial health.
The most recent analyst rating on (GB:CVSG) stock is a Hold with a £1420.00 price target. To see the full list of analyst forecasts on CVS Group plc stock, see the GB:CVSG Stock Forecast page.
CVS Group plc announced that David Wilton, the Non-executive Chairman, has purchased 2,500 ordinary shares, increasing his total interest to 12,500 shares, which represents 0.018% of the company’s total voting rights. This transaction, conducted on the London Stock Exchange, highlights a modest increase in insider ownership, potentially signaling confidence in the company’s future prospects.
The most recent analyst rating on (GB:CVSG) stock is a Hold with a £1420.00 price target. To see the full list of analyst forecasts on CVS Group plc stock, see the GB:CVSG Stock Forecast page.
CVS Group plc announced the purchase of 24,380 of its ordinary shares as part of a share buyback program initiated in October 2025. The shares were bought at prices ranging from 1,216.00 to 1,230.00 GBp and will be canceled, reducing the total number of shares in issue to 71,038,131. This move is part of a broader strategy to manage the company’s capital structure and potentially enhance shareholder value.
The most recent analyst rating on (GB:CVSG) stock is a Hold with a £1420.00 price target. To see the full list of analyst forecasts on CVS Group plc stock, see the GB:CVSG Stock Forecast page.
CVS Group plc, a leading veterinary services provider, announced the purchase of 24,590 of its own ordinary shares as part of its ongoing share buyback program. This transaction, executed with Joh. Berenberg, Gossler & Co. KG, is part of a broader initiative to enhance shareholder value and optimize the company’s capital structure. Following the cancellation of these shares, CVS will have 71,062,511 shares in issue, impacting the total number of voting rights and potentially influencing shareholder calculations under regulatory frameworks.
The most recent analyst rating on (GB:CVSG) stock is a Hold with a £1420.00 price target. To see the full list of analyst forecasts on CVS Group plc stock, see the GB:CVSG Stock Forecast page.
CVS Group plc has announced the grant of options under its 2025/2026 Save As You Earn (SAYE) share scheme, which is available to all employees. Executive Directors Richard Fairman, Robin Alfonso, and Paul Higgs have participated in the scheme, receiving options at a 10% discount to the average market price. A total of 370,637 options were granted, representing 0.52% of the company’s issued share capital, with the options exercisable from January 2029. This initiative is part of CVS’s strategy to engage employees and align their interests with the company’s long-term success.
The most recent analyst rating on (GB:CVSG) stock is a Hold with a £1420.00 price target. To see the full list of analyst forecasts on CVS Group plc stock, see the GB:CVSG Stock Forecast page.
CVS Group plc, a leading UK veterinary services provider, announced the issuance of 82 new ordinary shares following the exercise of options under the CVS Group 2024 SAYE Plan. This issuance brings the total issued share capital to 71,087,101 ordinary shares, each carrying one voting right. The announcement ensures transparency for shareholders regarding their voting rights and obligations under the FCA’s Disclosure Guidance and Transparency Rules.
The most recent analyst rating on (GB:CVSG) stock is a Hold with a £1420.00 price target. To see the full list of analyst forecasts on CVS Group plc stock, see the GB:CVSG Stock Forecast page.
CVS Group plc, a company involved in the veterinary services industry, announced a recent transaction involving the repurchase of its own shares. On November 27, 2025, CVS purchased 25,000 of its ordinary shares from Joh. Berenberg, Gossler & Co. KG, as part of a previously announced share buyback program. The shares were bought at prices ranging from 1,192.00 to 1,200.00 pence per share, with a volume-weighted average price of 1,198.95 pence. This move is part of CVS’s ongoing strategy to manage its capital structure, having repurchased a total of 653,682 shares since the start of the program. The repurchased shares are intended to be canceled, which could potentially enhance the value of remaining shares and impact shareholder returns.
The most recent analyst rating on (GB:CVSG) stock is a Hold with a £1420.00 price target. To see the full list of analyst forecasts on CVS Group plc stock, see the GB:CVSG Stock Forecast page.
CVS Group plc, a company involved in the veterinary services industry, announced the repurchase of 23,020 of its ordinary shares as part of its ongoing share buyback program. The shares were acquired at prices ranging from 1,182.00 GBp to 1,200.00 GBp, with a volume-weighted average price of 1,189.73 GBp. This transaction is part of a larger strategy to reduce the number of shares in circulation, which now stands at 71,112,101. The buyback is expected to enhance shareholder value by reducing the share count and potentially increasing earnings per share.
The most recent analyst rating on (GB:CVSG) stock is a Hold with a £1420.00 price target. To see the full list of analyst forecasts on CVS Group plc stock, see the GB:CVSG Stock Forecast page.
CVS Group plc, a company involved in the veterinary services industry, announced the repurchase of 25,000 of its ordinary shares as part of a share buyback program initiated in October 2025. The shares were bought at prices ranging from 1,170.00 GBp to 1,194.00 GBp, with a volume-weighted average price of 1,184.49 GBp. The company intends to cancel all purchased shares, resulting in a total of 71,135,121 shares in issue. This move is part of a broader strategy to manage the company’s capital structure and potentially enhance shareholder value.
The most recent analyst rating on (GB:CVSG) stock is a Hold with a £1420.00 price target. To see the full list of analyst forecasts on CVS Group plc stock, see the GB:CVSG Stock Forecast page.